60
Participants
Start Date
January 31, 2024
Primary Completion Date
June 16, 2025
Study Completion Date
June 16, 2025
Deuremidevir Hydrobromide for Suspension
"15 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg TID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension 3 times every day, total 15 times."
Placebo
"15 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg TID group: 5 subjects will receive placebo 3 times every day, total 15 times."
Shengjing Hospital of China Medical University, Shenyang
Children's Hospital of Soochow University, Suzhou
Shulan (hangzhou) Hosipital, Hangzhou
Xiamen Children's Hospital, Xiamen
Shenzhen Guangming District People's Hospital, Shenzhen
Liuzhou People's Hospital, Liuzhou
The first Affiliated hospital of Bengbu Medical University, Bengbu
Chongqing University Jiangjin Hospital, Chongqing
Xiamen Maternity and Child Healthcare Hospital, Xiamen
Guangdong Women and Children's Hospital and Health Institute, Guangzhou
Panyu Maternal and Child care Service centre of Guangzhou, Guangzhou
The Sceond Affiliated hospital of Shantou University Medical college, Shantou
Hainan women and children's Medical centre, Haikou
Sanmenxia Central Hospital, Sanmenxia
Changde First people's Hospital, Changde
Hunan Provincial Maternal and Child Health Care Hospital, Changsha
Jiangxi Maternal and Child Health, Nanchang
Liaocheng People's Hospital, Liaocheng
Mianyang Central Hospital, Mianyang
Children's Hospital of Zhejiang University School of Medicine, Hangzhou
Hangzhou First people's Hospital, Hangzhou
Linfen Central Hospital, Linfen
Vigonvita Life Sciences
INDUSTRY